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Abstract
Objective—To determine the predictors of pain improvement among patients being treated for
cancer-related pain over 12 months.
Methods—A secondary analysis of the Indiana Cancer Pain and Depression (INCPAD) trial was
performed. Patients participating in this telephone care management pain and depression
intervention trial (N=274, mean age=58.1±10.5 years, 66.1% women) were interviewed at
baseline, and 1, 3, 6, and 12 months. Pain improvement outcomes included both a continuous
measure (Brief Pain Inventory score) and a categorical measure (pain improved vs. pain not
improved). Predictor variables included change in depression, age, gender, race, marital status,
socioeconomic disadvantage, medical comorbidity, type of cancer, and phase of cancer.
Multivariable repeated measures were conducted adjusting for intervention group assignment,
baseline pain severity, and time in months since baseline assessment.
Results—Factors predicting both continuous and categorical pain improvement included
participating in the intervention group (beta=−.92, p<.001; OR=2.53, CI=1.65–3.89), greater
improvement in depression (beta=−.31, p=.003; OR=1.84, CI=1.35–2.51), higher socioeconomic
status (Socioeconomic Disadvantage Index; beta=.25, p=.034; OR=.73, CI=.56–.94), and fewer
comorbid conditions (beta=.20, p=.002; OR=.84, CI=.73–.96). Conversely, patients with more
severe pain at baseline or with recurrent or progressive cancer were less likely to experience
continuous or categorical pain improvement, respectively.
Conclusions—Effective management of depression and comorbid conditions along with
improvement of social services could be critical components of a comprehensive pain
management plan. Also, patients with more severe pain or with recurrent or progressive cancers
may require closer monitoring and adequate treatment of pain.
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It is estimated that about 1.6 million people were diagnosed with cancer in 2011 (1). For
some people, pain is the first symptom of cancer (2). Cancer-related pain can occur at any
time during the course of the disease (3) and may be caused by tumor infiltration/
involvement, diagnostic or therapeutic procedures, or cancer treatment (3, 4).
Prevalence of cancer-related pain varies based on cancer type, cancer trajectory, and
demographics. Up to 64% of patients experience cancer-related pain (5) and 82% have their
pain undertreated by analgesics (6). Undertreated pain can lead to lower quality of life (7, 8),
negative emotional states (8), interference with daily activities (9, 10), disability (11, 12),
and delay/disruption of cancer treatment (13, 14), all of which reduce the effectiveness of
the cancer treatment (15) and survival rates (3).
To avoid the consequences of undertreated pain, effective pain management is essential. In
addition to analgesics, other factors that influence pain include age (14), gender (14, 16–19),
race (14, 17, 20), socioeconomic status (6, 14, 21), comorbid conditions (19), type of cancer
(3, 22), and phase of cancer (5, 13). The complex interplay of these factors could explain
why some patients experience pain improvement while others report persistent pain despite
analgesic treatment. However, the majority of previous studies investigating factors that
influence pain have been cross-sectional in design.
The relationship between pain and depression is well known (23–32). Again, most of the
studies have been cross-sectional (23–26, 31, 32), so the temporal relationship is less well
documented. A small number of longitudinal studies have found current depression or
change in depression over time predicted subsequent pain among older adults in
communities or among patients from primary care clinics (27, 28, 30). But none of these
studies was conducted among cancer populations.
The Indiana Cancer Pain and Depression (INCPAD) study, a randomized clinical trial
implemented with patients who had different types and phases of cancer, tested a 12-month
telephone care management intervention designed to decrease pain and/or depression (33,
34). In the INCPAD trial, we found moderate pain improvement in the intervention group
compared to the usual-care group among patients being treated for cancer-related pain and/
or depression (p < .001) (34). Because the INCPAD study included multiple data collection
time points, it lends itself to repeated measures analysis, which is a particularly strong
method for studying longitudinal relationships between pain and other variables over time
(35). Therefore, we conducted a secondary analysis to determine which factors, besides the
intervention, predicted pain improvement. Specifically, our research question was: What are
the predictors of pain improvement among patients being treated for cancer-related pain
over 12 months?
2. Method
2.1. Sample and Setting
The design and baseline participant characteristics in the INCPAD study have been
published elsewhere (12, 33, 34). Patients with cancer-related pain and/or depression were
recruited from 16 urban and rural outpatient oncology clinics. Potential participants were
patients who had moderately severe cancer-related pain (a Brief Pain Inventory [BPI] worst
pain severity score ≥ 6), or depression (a Patient Health Questionnaire 9-item depression
scale [PHQ-9] score ≥ 10, with depressed mood and/or anhedonia) (24, 36–38). Cancer-
related pain had to be in the region of the primary tumor or cancer metastases and/or present
after the onset of the cancer treatment. Patients with cancer-related pain had to have tried at
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least one analgesic but still be experiencing pain. The study excluded those who did not
speak English, had moderately severe cognitive impairment as defined by a 6-item cognitive
screener (39), had schizophrenia or other psychoses, had a disability claim currently being
adjudicated for pain, were pregnant, were in hospice care, or had pre-existing pain
conditions unrelated to cancer.
A total of 405 participants with depression, cancer-related pain, or both were enrolled in the
INCPAD trial. For this secondary analysis, data from 274 participants who had cancer-
related pain (with or without depression) were analyzed: 137 in the intervention group and
137 in the usual care group. These 274 participants were enrolled from a group of 444
patients who met all entry criteria for cancer-related pain, thus yielding an enrollment rate of
62% of potentially eligible patients. The intervention group received centralized telephone
care management (telecare) focusing on optimizing medications to treat their cancer-related
pain and/or depression, while the usual-care group received care by their oncologists without
attempts by study personnel to influence their pain and/or depression treatment unless a
psychiatric emergency arose. Details of the telecare intervention have been described
previously (33). Our analysis combined the intervention and control groups to examine the
factors that influence pain management after controlling for treatment arm assignment.
2.2. Data Collection
Research assistants who conducted the phone interviews to collect data at baseline (T0), 1
month (T1), 3 months (T3), 6 months (T6), and 12 months (T12) were blinded to group
assignment. Medical record reviews from the oncology practice were performed during the
study. The study was approved by the Indiana University and Community Hospitals’
institutional review boards.
2.3. Measures
2.3.1 Outcome Variables—Pain improvement was measured by the Brief Pain Inventory
(BPI) severity scale and a single item assessing pain improvement, Pain Global Rating of
Improvement (PGRI). The BPI severity scale asks participants to rate their pain at its worst,
its least, and on average in the previous week, as well as their current pain on a 0 (no pain)
to 10 (pain as bad as you can imagine) point scale (36, 40). The mean of the 4 items was
determined, with higher scores reflecting more severe pain. The BPI had adequate internal
reliability (Cronbach’s α= .79) in the INCPAD study (33). The PGRI evaluates the
participants’ overall impression of the change in their pain since study enrollment, asking
whether their pain was worse, about the same, or better (33, 41). The PGRI has been found
to be more sensitive to changes in pain and better correlated with patient satisfaction than
the visual analog scale (42). Consensus guidelines for outcome assessment of pain
treatments in clinical trials recommend both a continuous measure of pain severity as well as
a patient-rated assessment of global improvement since the two measures capture somewhat
different, but complementary, dimensions of pain improvement (43).
2.3.2 Predictor Variables—Depression was measured using the Hopkins Symptom
Checklist 20-item depression scale (HSCL-20) (44). The 20 items are questions about how
much participants had been distressed by different symptoms of depression during the
previous 4 weeks on a 0 (not at all) to 5 (extremely) scale. The mean of these items is
calculated, yielding a range on a scale of 0 to 5, with higher scores reflecting more severe
depression. The HSCL-20 had good internal reliability (α = .79) in INCPAD (33).
Other variables examined as potential predictors included demographics (age, gender, race,
marital status, education, job status, and income) and baseline clinical factors (medical
comorbidity, type of cancer, and phase of cancer). The Socioeconomic Disadvantage (SED)
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Index is a composite score combining the three inter-related variables of education, income,
and employment status into a single variable; the SED Index is calculated by assigning 1
point each for low education (“less than high school”), unemployment (“unable to work due
to health or disability”), and low income (“not enough to make ends meet”) (12). Medical
comorbidity was measured using a checklist of eight diseases that has been shown to predict
health care utilization and mortality in medical populations (45). Type of cancer and phase
of cancer were obtained from participants’ medical records. Phase of cancer was categorized
as newly diagnosed, maintenance/disease-free, or recurrent/progressive.
2.4. Statistical Analysis
As noted, our research question was: What are the predictors of pain improvement among
patients being treated for cancer-related pain over 12 months? The two pain improvement
outcome variables were BPI severity and PGRI at T1, T3, T6, and T12. The BPI severity
score was a continuous variable. PGRI was recoded as a binary variable: 1 as “pain
improved” for participants who answered better on the PGRI, and 0 as “pain not improved”
for participants who answered worse or about the same on the PGRI.
Predictor variables included age, gender, race, marital status, SED Index, medical
comorbidity, type of cancer, and phase of cancer. We used a sophisticated method to
examine the temporal influence of depression improvement on the sequent pain outcome
(28). Figure 1 diagrams the repeated measures modeling for the predictive relationship:
preceding improvement in depression predicting subsequent pain improvement over 12
months. Specifically, we modeled the relationship of HSCL-20 change scores between
baseline and 1 month (T1–T0) to BPI or PGRI at T1; between 1 month and 3 months (T1–
T3) to BPI or PGRI at T3; between 3 months and 6 months (T3–T6) to BPI or PGRI at T6;
and between 6 months and 12 months (T6–T12) to BPI or PGRI at T12. Data from study
participants at each time point were analyzed by the generalized linear mixed effects models
for repeated measures (MMRM) to elucidate the relationship between depression change
and pain, with the former as a predictor and latter as the outcome. In this analysis, random
subject effect was incorporated into the model to accommodate the potential correlation
among the repeatedly measured outcomes within subjects. We developed a full model by
adjusting for group assignment, baseline BPI severity, and time in months since baseline
assessment. The analyses were performed using PRO MIXED of SAS Version 9.1 (SAS




The baseline characteristics of the participants are shown in Table 1. Two-thirds of the
participants were female, 77% were white, and 65% had both cancer-related pain and
depression upon enrollment in the study. Their mean age was 58 years, with a range from 23
to 85 years old. At baseline, participants reported moderate pain intensity on the BPI scale.
There was a wide distribution of types and phases of cancer, a consequence of screening all
patients attending the participating oncology practices. Previous analyses showed that, as
expected from the randomized allocation design of the trial, the intervention and usual care
groups were similar in all baseline characteristics (34). Compared to the usual care group,
patients in the telecare intervention group had significantly greater pain improvement (effect
size of .46 and .39 at 6 and 12 months, p < .001) and depression improvement (effect size
of .45 and .41 at 6 and 12 months, p < .001) (34).
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3.2. Predictors of Pain Improvement
Table 2 summarizes the results from the multivariable MMRM for the two outcome
variables. As expected, being in the intervention group and having lower baseline pain
severity were strongly associated with better pain outcomes over 12 months. Also, the time
in months since baseline assessment was significantly associated with reduced BPI scores.
Other independent predictors of improvement in BPI severity over 12 months were better
socioeconomic status (i.e., a lower SED Index score) and less medical comorbidity.
Importantly, improvement in depression was the strongest predictor (t = −2.97, p = .003). A
preceding 1-point improvement in HSCL-20 depression severity predicted subsequent
reduction in BPI pain severity of .31 points.
Similar to the BPI severity model, independent predictors of Pain Global Rating of
Improvement (PGRI) over 12 months included being in the intervention group, time in
months since enrollment, better socioeconomic status, and less medical comorbidity. Again,
improvement in depression was the strongest predictor (OR = 1.84 for each 1-point
improvement in HSCL-20 depression score, 95% CI = 1.35–2.51). An additional predictor
was cancer phase: participants whose cancer was newly-diagnosed were more than twice as
likely to experience pain improvement compared with those with recurrent or progressive
cancer. Although the association between phase of cancer and BPI severity did not reach
significance, there was a trend towards an association (p = .07).
4. Discussion
Our study makes several important contributions to the literature about the relationship
between pain and depression. First, we used a sophisticated analytical strategy which
strengthens conclusion regarding the predictive relationships between depression and pain.
Second, this is the first longitudinal study examining the depression-pain relationship in
cancer populations. Third, we found that preceding improvement in depression is a strong
predictor of subsequent pain.
Our analytical strategy is particularly strong. Conceptually, the INCPAD study is a clinical
trial treating both cancer-related pain and depression (33). Depression (HSCL-20 score) was
a dynamic variable that changed in both the intervention and usual care groups over the 12-
month study period (34). Because of the longitudinal nature of the INCPAD study, we were
able to assess whether change in depression during preceding time intervals predicted
reduced pain severity and pain improvement at subsequent time points repeatedly over a 12-
month period. In addition, the multivariate MMRM applied in our study allows repeated
measures from the same subject to share a common random effect (46, 47). This analysis
helps to establish within-subject associations between pain and depression. Therefore, the
MMRM method may provide a better fit model than the population averaged model, such as
generalized estimating equations (GEE) analysis used to assess group average associations
between pain and depression in previous longitudinal studies (27, 30). Our use of MMRM
analysis is a sophisticated approach to examine the temporal relationship between
depression and pain but it has not been applied among cancer patients (26, 28). Furthermore,
we adjusted for multiple important confounders: intervention assignment, baseline pain
severity, and the passage of time. Even controlling for these factors, the predictors identified
from our analysis still showed significant effects on pain improvement.
The important finding in our study is the beneficial association between improvement in
depression and pain outcomes in cancer patients. This result is not only consistent with
previous studies that have suggested a predictive relationship from depression to pain in
geriatric and primary care populations (27–30), but also supports a similar relationship in the
cancer population. Clinically, it is suggested that effectively treating comorbid depression in
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patients with cancer-related pain may be an important adjunct to optimizing analgesic
therapy and other pain-specific treatments. This finding from our study highlights the
potential importance of screening for, monitoring, and treating both symptoms concurrently
in cancer patients.
Socioeconomic disadvantage and pain risk have been positively linked in patients with
musculoskeletal, sciatica, ulcer, and neuropathic pain (21). Consistent with this, our analysis
showed that participants with better socioeconomic status were more likely to experience
improvement in cancer-related pain. Other studies have found that patients with lower
incomes and educational attainment had a high risk of undertreated cancer-related pain (6,
13). Socioeconomically disadvantaged patients may be more likely to have negative pain
beliefs, possess little or no health insurance, have less social support, and use passive coping
styles, all of which may contribute to uncontrolled chronic cancer-related pain (6). To cancer
patients who are disadvantaged socioeconomically, clear and appropriate pain education,
additional care management, and supportive social services may be necessary when a pain
management program is implemented. Referrals to social workers and public welfare
agencies as well as resources for cancer survivors may be important to consider for this
vulnerable subgroup of the population.
Patients with a greater number of comorbid medical conditions were less likely to report
improvement in their cancer-related pain in our study. The National Health Interview Survey
has shown that a higher number of comorbid conditions were significantly associated with
poor health status and disability among cancer patients (48). From our findings, it is
suggested that cancer patients with pre-existing chronic diseases are more likely to develop
persistent cancer-related pain, which could contribute to poor health status and disability (8,
11, 12). Effective management of pre-existing chronic conditions may further optimize
treatment outcomes in patients with cancer-related pain.
Not surprisingly, we found that patients with recurrent or progressive cancer had worse pain
outcomes over 12 months than those who were newly-diagnosed. The most difficult to treat
cancer-related pain is the pain caused by tumor involvement, where tumor mass has invaded
surrounding or distant structures (3, 15). Therefore, patients with cancer-related pain in the
recurrent or progressive phase of their illness may require more frequent monitoring of their
pain and more aggressive pain treatment. In contrast, a recent diagnosis of cancer seemed to
be an independent predictor of better pain outcomes. It may be that dysphoric mood is
reactive and time limited among a subset of newly- diagnosed cancer patients. Likewise,
pain may also be more transient in some of these patients, being a consequence of surgery,
radiation, or chemotherapeutic neuropathy, and may subsequently resolve following
completion of treatment. In such cases, pain may simply lag behind the resolution of
depressed mood rather than being causally related.
Disparities of pain management have been observed in several populations including older
age, female gender, and minority race (14). Studies found older age was associated with
inadequate pain management among patients in the nursing home or hospital (14, 49). Our
study suggested that age is not related to pain improvement among those from the outpatient
oncology clinic. For gender, one study found that more female patients had undertreated
pain than their counterparts (14). Women tended to be careless at times about taking pain
medication and were more likely to stop taking the pain medication when they felt better
(50). We did not see a relationship between gender and pain improvement in our study, a
finding similar to that of other studies conducted in cancer patients (51, 52). Finally, some
earlier studies indicated that ethnic minority patients reported undertreated pain because
those patients did not receive an adequate amount of analgesics (14, 18, 53). In our study,
race was not associated with either pain improvement outcome. However, we could not
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ascertain whether the ethnic minority participants in our study had received an adequate
amount of analgesics.
Our study has several limitations. First, the INCPAD enrollment criteria created a study
sample enriched with depressed patients with pain. These patients may not be representative
of cancer patients in general, even though their demographic and disease characteristics are
similar. Whether the finding demonstrated in our sample would be similar in cancer
populations with lesser degrees of pain or depression should be further explored. Second, it
is possible that our finding of improvement in depression over a preceding time interval
predicting subsequent pain might be partly explained by pain improvement in the preceding
interval. Therefore, an alternative explanation of our data is that reduced pain at a particular
time point represented preceding pain improvement, which may have influenced
improvement in depression. Although our repeated measures analytical strategy modeling
improvement in depression over multiple time intervals to predict end-of-interval pain status
at multiple time points strengthens the case for a temporal linkage from improvement in
depression to lower pain, it does not establish this reciprocal relationship with complete
certainty. Nonetheless, our findings are consistent with results from longitudinal studies in
noncancer populations that have shown that change in depression predicts pain outcomes
(28).
Our findings from this 12-month longitudinal study of pain outcomes in patients with
cancer-related pain suggest that several factors may be important to consider in developing a
more comprehensive approach to pain management. For example, proactively managing
depression and other comorbid conditions, as well as enhancing sufficient social support,
might be useful adjuncts to pain treatment, particularly in patients whose pain is not
responding to standard analgesic management. Also, patients with more severe pain at
baseline as well as those with recurrent or progressive cancers may benefit from closer
monitoring of their pain and, in some cases, more aggressive pain treatment. Gaining an
understanding of some of the demographic and clinical factors that influence pain outcomes
might enable clinicians to tailor and augment treatment in selected patients with more
persistent or refractory cancer-related pain.
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Glossary
BPI Brief Pain Inventory
HSCL-20 Hopkins Symptom Checklist 20-item depression scale
INCPAD Indiana Cancer Pain and Depression
MMRM Mixed Effects Models for Repeated Measures
PGRI Pain Global Rating of Improvement
PHQ-9 Patient Health Questionnaire 9-item depression scale
SED Socioeconomic Disadvantage
T0 baseline data collection
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T1 1-month data collection
T3 3-month data collection
T6 6-month data collection
T12 12-month data collection
Telecare centralized telephone care management
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Inventory (BPI) severity score or Pain Global Rating of Improvement (PGRI) over 12
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Table 1
Baseline Characteristics of Participants with Cancer-Related Pain (T0)
Baseline Characteristics N =274
Mean (SD)
Age 58.08 (10.54)
SED Indexa 1.30 (0.98)
Medical Comorbidity (no. of diseases) 2.09 (1.68)
Baseline Cancer-related Pain (BPI severity score, 0–10 scale) 5.22 (1.82)
n (%)
Group
 Intervention 137 (50.0)
 Control 137 (50.0)
Symptom
 Pain 96 (35.0)
 Pain and Depression 178 (65.0)
Gender
 Male 93 (33.9)
 Female 181 (66.1)
Race
 White 212 (77.4)
 Black and othersb 62 (22.6)
Marital Status
 Married 130 (47.4)
 Unmarried 144 (52.6)
Type of Cancer
 Breast 70 (25.6)
 Lung 53 (19.3)
 Gastrointestinal 51 (18.6)
 Lymphoma/Hematological 40 (14.6)
 Genitourinary 27 (9.9)
 Other 33 (12.0)
Phase of Cancer
 Newly-diagnosed 104 (38.0)
 Maintenance or disease-free 110 (40.2)
 Recurrent or progressive 60 (21.9)
Note: BPI = Brief Pain Inventory; SED Index = Socioeconomic Disadvantage Index.
a
The SED Index included variables of education (“less than high school” = 1 point), employment (“unable to work due to health or disability” = 1
point), and income (“not enough” = 1 point).
bOther races were only 1.8% (n = 5) in this sample.
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